Since a human oral cancer cell line (B88) exhibited constitutively activated NF-κB activity in our previous studies (16,17), we hypothesized that the downregulation of anti-apoptotic proteins through the suppression of NF-κB activity would be a promising strategy for the treatment of patients with oral cancer. The gene discussed is NFKB1; the disease is lip and oral cavity carcinoma.